Samsung Bioepis and Harrow Present Interim Data from a Large-Scale Post-Marketing Surveillance Study on SB11 (BYOOVIZ® / AMELIVU®), a Biosimilar to Lucentis (ranibizumab), at ASRS 2026

Data ReadoutpositiveSB11 (BYOOVIZ®/AMELIVU®)LucentisPositive

AI Analysis

Summary

Samsung Bioepis and Harrow presented interim data from a large-scale post-marketing surveillance study on SB11 (BYOOVIZ®/AMELIVU®), a biosimilar to Lucentis, at ASRS 2026. The data presentation demonstrates ongoing clinical validation of the ranibizumab biosimilar in real-world use.

Clinical Trial Data

Outcome Details

Interim data from large-scale post-marketing surveillance study presented at ASRS 2026

Importance:5/10

Sentiment:

0.50

biosimilarpost-marketing surveillanceophthalmologyranibizumabASRS conference

Related Companies

$HROW

Read the original article

Published by yahoo_finance on July 20, 2026 12:00 PM

Read Original